Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: binodenoson
Drug: adenosine

First Posted Date: 2009-07-23

Last Posted Date: 2012-06-01

Lead Sponsor: Pfizer

Target Recruit Count: 578

Registration Number: NCT00944970

This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder

Completed

Conditions: Overactive Bladder

Interventions: Drug: Fesoterodine
Behavioral: Your Way

First Posted Date: 2009-07-22

Last Posted Date: 2018-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 774

Registration Number: NCT00943735

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Phase 4

Completed

Conditions: Cancer

Interventions: Drug: dalteparin

First Posted Date: 2009-07-21

Last Posted Date: 2024-04-18

Lead Sponsor: Pfizer

Target Recruit Count: 338

Registration Number: NCT00942968

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Bay Area Cancer Research Group, Pleasant Hill, California, United States
🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

and more 39 locations

Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: PF-05212384 (also known as PKI-587)

First Posted Date: 2009-07-16

Last Posted Date: 2018-11-02

Lead Sponsor: Pfizer

Target Recruit Count: 78

Registration Number: NCT00940498

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States

and more 5 locations

An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Dimebon

First Posted Date: 2009-07-15

Last Posted Date: 2012-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 649

Registration Number: NCT00939783

Locations: 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico

Relative Drug Exposures Of Two Formulations of PF-02341066

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-02341066

First Posted Date: 2009-07-15

Last Posted Date: 2011-10-24

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00939731

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

Phase 4

Completed

Conditions: Aspergillosis
Candidemia

Interventions: Drug: anidulafungin and voriconazole

First Posted Date: 2009-07-15

Last Posted Date: 2010-02-09

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00940017

Locations: 🇺🇸
Pfizer Investigational Site, Hartford, Connecticut, United States

A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)

Phase 1

Terminated

Conditions: Bipolar Disorder
Depression

Interventions: Drug: PF-04455242

First Posted Date: 2009-07-15

Last Posted Date: 2010-02-08

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00939887

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate

Phase 4

Completed

Conditions: Bacterial Infection

Interventions: Drug: doxycycline monohydrate tablet
Drug: doxycycline carragenate tablet

First Posted Date: 2009-07-15

Last Posted Date: 2009-12-23

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00939562

Locations: 🇮🇳
Pfizer Investigational Site, Ahmedabad, Gujarat, India

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: PF-04171327 10 mg
Drug: PF-04171327 25 mg
Other: Placebo
Drug: Prednisone 5 mg
Other: Prednisone Placebo
Other: Placebo for PF-04171327

First Posted Date: 2009-07-14

Last Posted Date: 2023-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 86

Registration Number: NCT00938587

Locations: 🇺🇸
Anniston Medical Clinic, PC, Anniston, Alabama, United States
🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Allergy, Asthma, Arthritis and Lung, Daytona Beach, Florida, United States

and more 38 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy